In hematologic malignancies, IL3-Lamp2B–engineered exosomes loaded with imatinib or BCR-ABL siRNA selectively targeted chronic myeloid leukemia cells, reducing tumour burden without overt systemic toxicity (69). This evidence concerns the gene IL3 and neoplasm.